Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.

Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD.

N Engl J Med. 2010 Mar 11;362(10):875-85. doi: 10.1056/NEJMoa0905680.

2.

MET and MST1R as prognostic factors for classical Hodgkin's lymphoma.

Wha Koh Y, Park C, Hyun Yoon D, Suh C, Huh J.

Mod Pathol. 2013 Sep;26(9):1172-82. doi: 10.1038/modpathol.2013.64. Epub 2013 Apr 5.

3.

LGALS3 as a prognostic factor for classical Hodgkin's lymphoma.

Koh YW, Jung SJ, Park CS, Yoon DH, Suh C, Huh J.

Mod Pathol. 2014 Oct;27(10):1338-44. doi: 10.1038/modpathol.2014.38. Epub 2014 Mar 7.

4.

Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma.

Kamper P, Bendix K, Hamilton-Dutoit S, Honoré B, Nyengaard JR, d'Amore F.

Haematologica. 2011 Feb;96(2):269-76. doi: 10.3324/haematol.2010.031542. Epub 2010 Nov 11.

5.

Toward a personalized treatment of Hodgkin's disease.

DeVita VT Jr, Costa J.

N Engl J Med. 2010 Mar 11;362(10):942-3. doi: 10.1056/NEJMe0912481. No abstract available.

PMID:
20220189
6.

Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma.

Azambuja D, Natkunam Y, Biasoli I, Lossos IS, Anderson MW, Morais JC, Spector N.

Ann Oncol. 2012 Mar;23(3):736-42. doi: 10.1093/annonc/mdr157. Epub 2011 May 20.

7.

The prognostic role of tumor-associated macrophages and dendritic cells in classic Hodgkin's lymphoma.

Abdou AG, Asaad NY, Loay I, Shabaan M, Badr N.

J Environ Pathol Toxicol Oncol. 2013;32(4):289-305.

PMID:
24579783
8.

Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma.

Steidl C, Diepstra A, Lee T, Chan FC, Farinha P, Tan K, Telenius A, Barclay L, Shah SP, Connors JM, van den Berg A, Gascoyne RD.

Blood. 2012 Oct 25;120(17):3530-40. doi: 10.1182/blood-2012-06-439570. Epub 2012 Sep 5.

9.

The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma.

Jakovic LR, Mihaljevic BS, Perunicic Jovanovic MD, Bogdanovic AD, Andjelic BM, Bumbasirevic VZ.

Leuk Lymphoma. 2011 Oct;52(10):1913-9. doi: 10.3109/10428194.2011.580026. Epub 2011 Jun 12.

PMID:
21663512
10.

Tumour-associated mast cells in classical Hodgkin's lymphoma: correlation with histological subtype, other tumour-infiltrating inflammatory cell subsets and outcome.

Andersen MD, Kamper P, Nielsen PS, Bendix K, Riber-Hansen R, Steiniche T, Hamilton-Dutoit S, Clausen M, d'Amore F.

Eur J Haematol. 2016 Mar;96(3):252-9. doi: 10.1111/ejh.12583. Epub 2015 Jun 8.

PMID:
25963595
11.

CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma.

Harris JA, Jain S, Ren Q, Zarineh A, Liu C, Ibrahim S.

Diagn Pathol. 2012 Jan 30;7:12. doi: 10.1186/1746-1596-7-12.

12.

HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma.

Diepstra A, van Imhoff GW, Karim-Kos HE, van den Berg A, te Meerman GJ, Niens M, Nolte IM, Bastiaannet E, Schaapveld M, Vellenga E, Poppema S.

J Clin Oncol. 2007 Jul 20;25(21):3101-8. Epub 2007 May 29.

PMID:
17536082
13.

Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure.

Liao Z, Ha CS, Vlachaki MT, Hagemeister F, Cabanillas F, Hess M, Tucker S, Cox JD.

Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):971-7.

PMID:
11429225
14.

Prognostic significance of Bcl-2, tumor-associated macrophages, and total neoplastic and inflammatory lymph node involvement in advanced stage classical Hodgkin's lymphoma.

Jakovic LR, Mihaljevic BS, Jovanovic MD, Bogdanovic AD, Andjelic BM, Bumbasirevic VZ.

Onkologie. 2012;35(12):733-9. doi: 10.1159/000343664. Epub 2012 Nov 20.

PMID:
23207618
15.

[Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].

Fu XH, Wang SS, Huang Y, Wang B, Huang HQ, Zhang L, Sun XF, Xu RH, Lin TY.

Ai Zheng. 2006 Aug;25(8):1013-8. Chinese.

PMID:
16965685
16.

Proliferation characteristics in pediatric Hodgkin's lymphoma point to a cell cycle arrest in the G(1) phase.

Tiemann M, Claviez A, Lüders H, Zimmermann M, Schellong G, Dörffel W, Parwaresch R.

Mod Pathol. 2005 Nov;18(11):1440-7.

18.

Expression of p21 and MDM-2 proteins on tumor cells in responding and non-responding patients with Hodgkin's disease.

Smolewski P, Niewiadomska H, Krykowski E, Robak T.

Neoplasma. 1999;46(4):212-8.

PMID:
10613600
19.

Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma.

Sánchez-Espiridión B, Martin-Moreno AM, Montalbán C, Medeiros LJ, Vega F, Younes A, Piris MA, Garcia JF.

Haematologica. 2012 Jul;97(7):1080-4. doi: 10.3324/haematol.2011.055459. Epub 2012 Feb 7.

20.

Longer failure-free survival interval of Epstein-Barr virus-associated classical Hodgkin's lymphoma: a single-institution study.

Krugmann J, Tzankov A, Gschwendtner A, Fischhofer M, Greil R, Fend F, Dirnhofer S.

Mod Pathol. 2003 Jun;16(6):566-73.

Supplemental Content

Support Center